Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients
抄録
Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAFmutant or NRASmutant) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2?4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy.
Article
ACTA DERMATO-VENEREOLOGICA. 97:1212-1218(2018)
収録刊行物
-
- ACTA DERMATO-VENEREOLOGICA
-
ACTA DERMATO-VENEREOLOGICA 97 (10), 1212-1218, 2017-11
ACTA DERMATO-VENEREOLOGICA
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1050564288890062976
-
- NII論文ID
- 120007100119
-
- HANDLE
- 10091/00021019
-
- ISSN
- 00015555
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- IRDB
- CiNii Articles